Haloperoxidase compositions and uses thereof

A technology of haloperoxide and peroxidase, applied in drug combination, oxidoreductase, enzyme and other directions, can solve the problem of difficult to treat gram-negative bacterial infection

Pending Publication Date: 2021-03-16
罗伯特 C 艾伦 +1
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Gram-negative bacterial infections are difficult to treat

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Haloperoxidase compositions and uses thereof
  • Haloperoxidase compositions and uses thereof
  • Haloperoxidase compositions and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0135] Example 1: Limulus amebocyte lysate assay

[0136] Lipopolysaccharide (LPS) and lipid A were quantified using the chromogenic Limulus amoebocyte lysate (LAL) assay (LAL Endochrome-K, Charles River Endosafe). Briefly, the LAL assay is a kinetic colorimetric assay that detects and measures color development. Endotoxin activation of LAL coagulase is measured as the enzymatic (hydrolytic) cleavage of a synthetic chromogenic substrate, releasing p-nitroaniline (pNA), which can be measured by absorbance at a wavelength of 405 nm in a microplate spectrophotometer Quantify. The kinetic measurement at which the maximum color change (slope) is reached is used as a measure of the activity of the endotoxin present. Calibration standards are measured to generate standard curves and equations for calculating the endotoxin activity of assay samples. The amount of endotoxin present in a sample can be specified as Endotoxin Units (EU).

[0137] The endotoxin mass / well of a series of...

Embodiment 2

[0138] Example 2: Inhibition of LPS by haloperoxidase

[0139] MPO, EPO or GO were pre-incubated with LPS or lipid A for 30 min at 37°C. After pre-incubation, the limulus lysate solution was added and the seconds to reach the maximum color change (slope) were measured. The equation derived using the LPS standard ( figure 1 ), the time to maximum slope was converted to equivalent LPS mass and based on the difference between the activity of the expected mass (e.g., endotoxin without enzyme) and the actual measured LPS activity (e.g., endotoxin with enzyme) Calculate the inhibition rate expressed as a percentage.

[0140] Such as figure 2 As shown, MPO significantly inhibits LPS, and the inhibition of LPS is proportional to the natural logarithm (Ln) of the mass of MPO. 1 mg MPO inhibited 90.8% of the activity of 5 ng LPS (ie 4.5 ng LPS). 0.01 mg MPO inhibited the activity of 5 ng LPS by 27.7% (ie 1.4 ng LPS). With LPS mass held constant and MPO mass varied, the percent in...

Embodiment 3

[0143] Example 3: Inhibition of Lipid A Endotoxin Activity by MPO and EPO

[0144] Lipid A, the toxic component of LPS, consists of two glucosamine units linked to phosphate groups and usually six hydrophobic fatty acids that anchor it to the outer membrane of Gram-negative bacteria. Purified lipid A is toxic and its endotoxin activity can be measured by LAL assay.

[0145] Inhibition of MPO and EPO was tested using diphosphoryl lipid A from E. coli F583 (Sigma Aldrich, L5399) and the chromogenic LAL assay described above. The hydrophobic nature of Lipid A can complicate the preparation of aqueous standards. Figure 4 The data shown in illustrates the reproducibility of aqueous lipid A standards as measured by chromogenic LAL activity up to 5.75 hours after preparation. The endotoxin unit activity per mass of lipid A was lower than that described by the manufacturer (i.e., ≥1 × 10 6 EU / mg), and the activity showed detectable degradation within hours. Therefore, LPS or Lipi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A method of treating at least one of septicemia, endotoxemia or a bacterial infection in a subject can include administering to the subject a composition containing a therapeutically effective amountof a haloperoxidase. The haloperoxidase can be myeloperoxidase or eosinophil peroxidase. The haloperoxidase can inhibit lipopolysaccharide or Lipid A activity in the subject; as a non-limiting example, the haloperoxidase is not engaged in active haloperoxidase activity, but available for LPS or Lipid A binding and inhibition.

Description

technical field [0001] The present disclosure relates to compositions comprising haloperoxidases, and the use of such compositions in the treatment of bacterial infections, particularly Gram-negative bacterial infections and endotoxin-related conditions. Background technique [0002] Any discussion of prior art throughout this specification should not be considered as an acknowledgment that such prior art is widely known or forms part of the common general knowledge in the field. [0003] Bacterial toxins promote infection and disease by directly damaging host tissues and by modulating the host's immune system. There are two types of bacterial toxins, exotoxins and endotoxins. Exotoxins are secreted by bacteria, and cause various symptoms depending on the species of bacteria secreting the exotoxin. Endotoxins, also known as lipopolysaccharides (LPS), are potent stimulators of the host immune system. They contain a toxic lipid component called lipid A as well as O antigen ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N7/00C12N9/22C12P19/34
CPCA01K2267/0337A01K2227/105A01K2207/20C12N9/0065A61K38/44A61P31/04Y02A50/30A61K9/0019A61K45/06A61P29/00A61P17/02C12Y111/02002A61P7/00C12Y111/01007
Inventor 罗伯特·C·艾伦杰克逊·T·斯蒂芬斯
Owner 罗伯特 C 艾伦
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap